Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WINT has traded volume over the Authorized Shares of 120,000,000. It's only 11:30 am.
Hold on your shares and squeeze them shorts
WINT SECURITY DETAILS
Authorized Shares
120,000,000
11/15/2022
Outstanding Shares
38,610,119
11/15/2022
Restricted
8,596,452
11/15/2022
Unrestricted
30,013,667
11/15/2022
Held at DTC
29,968,550
11/15/2022
BONZAIIII!!!!! nice moring jog so far here
WINT: Was hard to find that, too; notwithstanding that 'EZMoney' had already posted about it, but he gave no LINK to it. So, I had to copy-&-paste what he had posted, right into Google's front door. Hopefully, some more SUBSTANTIVE news, PR's, or Tweets, soon hit the media airwaves regarding WHAT kind of gadget, drugs, 'AI', or whatever, STUFF they have "Patented".
WINT: They got a gadget Patent for JUMP-STARTING critical Heart failures.
What is the gist of it?
WINT: And here's that (obscure) news; 2-minutes before the Close, yesterday.
https://www.streetinsider.com/Trader+Talk/Windtree+Therapeutics%2C+Inc.+%28WINT%29+granted+US+patent+related+to+heart+failure+treatment/21253146.html
(But you must be a MEMBER to read it --- I'm NOT a member there.)
WINT: And suddenly --- when BARCHART (belatedly) popped-open just now --- WINT bestrides the TOP of it, right out of NOWHERE!! WHAT?????
https://www.barchart.com/investing-ideas/penny-stocks?orderBy=symbolName&orderDir=desc
////////////////////////////////////////////////////////////////////////////////////////
$WINT: Now 0.30......... boooommmmmmmmmmmmmm
Thats how u trade........ good news is good news
Lets see $1 today
GO $WINT
Thank you very much! :)
$WINT: There is news..... Big News on Heart Patent
I already read it earlier........ now $0.25
GO $WINT
Flying higher on no news
$WINT: OHhhhhh yaaaaa...... that was a fun one
Waiting on $TMNA to get her jets going now
GO $WINT
Out at .2360s thanks
$WINT: I agree.... now at $0.18.
Letssssssssssssss Finnnnnnnnnnnnn GOOOOOooooooooooo
GO $WINT
Even better now at $.185 a share. But hold a week or 2 and it may be in the single copper digit. That would make for a great averaging down.
Great time for share buyback at $.26 price per share!
35 times 10 day average volume. What am I missing?
This phase II meets end point sure as heck makes this worth many times its current cap of $10 mil just simply a bargain basement price
Windtree Therapeutics, Inc. (NASDAQ: WINT) shares are rising on a positive mid-stage readout.
Probably won't see any real movement until next earnings when the show less amount of debit's.
Wow that’s Amazing $$$$
Windtree’s Pipeline Attracts Two Chinese Firms in $80M Deal
Big Pharmaceutical Buyout Candidate,
Pennsylvania biotech Windtree Therapeutics has entered into a $78.9-million deal with Hong Kong-based Lee’s Pharmaceutical and its China affiliate, Zhaoke Pharmaceutical. At the core of the agreement are Windtree’s pulmonary pipeline treatments, particularly the KL4 surfactant and the drug-device combination AEROSURF, both for respiratory distress syndrome in preterm infants.
Lee and Zhaoke had previously won a regional license for KL4 and AEROSURF, paying an upfront $1 million for rights to Windtree’s pipeline products in the Greater China area. This week’s deal expands that coverage globally. In turn, the Asian companies will assume all funding responsibility over development, manufacturing, commercialization and intellectual property activities, while Windtree will remain entitled to commercial milestones and potential double-digit royalties.
After its execution, the agreement will conclude all of Windtree’s ongoing maintenance and operating costs for KL4.
inice missed wint
Big-time gains today with massive volume.
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement
Windtree may receive up to $78.9 million in development, regulatory and commercial milestones plus low double digit royaltiesDevelopment and all other costs to be assumed by Lee’s Pharmaceutical and Zhaoke Pharmaceutical
WARRINGTON, Pa., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today announced it has entered into a global licensing agreement with Lee’s Pharmaceutical (HK) Limited, (Lee’s) and its affiliate Zhaoke Pharmaceutical (Hefei) Co. Ltd., (Zhaoke) for the development and commercialization of Windtree’s acute pulmonary pipeline treatments KL4 surfactant and drug/device combination, AEROSURF®, for the treatment of preterm infants with respiratory distress syndrome (RDS) and other potential applications. RDS often occurs in preterm infants when the lung is not fully developed with natural lung surfactant and may require surfactant therapy to sustain life.
“We are excited to announce this global licensing transaction for our KL4 surfactant platform given the value it can provide to the Company, its shareholders and critically ill patients,” said Craig Fraser, President and Chief Executive Officer of Windtree. “The out-licensing of the KL4 platform supports our portfolio prioritization and increases non-dilutive resources to progressing istaroxime on the significant opportunity in the major markets of cardiogenic shock and heart failure where recent positive data has created what we believe could be a relatively fast and less expensive developmental pathway in cardiogenic shock. Given the clinical potential of KL4 surfactant and AEROSURF to help preterm infants with RDS, we desired a partner who was capable of fully assuming execution of the platform and could build value. Over the past few years, we have worked with the Lee’s and Zhaoke’s teams as they invested significantly in building manufacturing, analytical and clinical capabilities to move the KL4 platform into late-stage development. This transaction strengthens Windtree’s resources for its core programs and delivers significant potential value to its shareholders on assets we were no longer progressing ourselves.”
Under terms of the global license agreement, Lee’s and Zhaoke will receive a global license to develop and commercialize Surfaxin®, lyophilized lucinactant and AEROSURF for any potential indications and applications. Lee’s and Zhaoke will be responsible for funding all development, intellectual property, manufacturing, and commercialization activities and provide developmental, regulatory and eventual commercial sales milestones for Windtree of up to $78.9 million plus potential double-digit royalties. Windtree had previously granted a regional license to Lee’s and Zhaoke for KL4 and AEROSURF for the territory of Greater China for which Windtree received an upfront payment, and this new agreement expands that territory globally. With the execution of this agreement, Windtree will no longer have ongoing maintenance and operating costs for the KL4 platform.
About Lyophilized Lucinactant and AEROSURF®
Lyophilized lucinactant is an investigational synthetic peptide (KL4 surfactant) containing drug product that is being developed to improve the management of RDS in premature infants who may not have fully developed natural lung surfactant and may require surfactant therapy to sustain life. AEROSURF® (lucinactant for inhalation) is a drug/device combination designed to deliver aerosolized KL4 surfactant noninvasively using our proprietary ADS technology and potentially may meaningfully reduce the use of invasive endotracheal intubation and mechanical ventilation. We believe that AEROSURF, if approved, may meaningfully reduce the number of premature infants who are subjected to invasive surfactant administration, and potentially provide transformative clinical and pharmacoeconomic benefits. The FDA has granted Fast Track designation for AEROSURF to treat RDS and the program has Orphan Drug designation.
About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include: risks and uncertainties associated with the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the Company’s clinical trials, clinical trial timelines or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates; the impacts of political unrest, including as a result geopolitical tension, including escalation in the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and any additional resulting sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets; the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materi
WINT news coming between now and the next 4 weeks. WHy are you all asleep here?
who revived this taxidermy horse? It wasn't public relations.
Filthy corrupt MM shorts are pulling all their BS games to shake out buyers so the criminal shorts can cover before the market runs it back up.
Thanks. I hope you're right about getting it shoved down their throats.
It was on Twitter last week, if it breaks $2.50 again it could start squeezing again to new morning highs, if it was to trade over three I would take most off, anything in the high twos would not be a bad idea to take some off, the short criminals like to fade this one, perhaps today will be the day they can't get away with their criminal behavior and get their premarket shorting shoved down their throats.
Where did you see that and do you think they can run it to 3 today? I bought at 2.48 and 2.36 this morning.
The reddit crowd must be at it again, there was some chatter that they wanted to rip the shorts a new one last week, with some of them saying they planned a major short squeeze attack that they wanted to run it up over three today, with so many corrupt and criminal like shorts known to be here.
Have any idea what is going on with WINT today?
Have any idea what is going on with WINT this morning?
All the news and the stock sky rockets to +.0001 \o/ Smh
Followers
|
106
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3271
|
Created
|
08/13/05
|
Type
|
Free
|
Moderators |
Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant therapies to treat respiratory disorders and diseases based on its KL4 surfactant and capillary aerosol-generating technologies. Its development stage products include Surfaxin, a synthetic, peptide-containing surfactant in phase III clinical trial for the prevention of respiratory distress syndrome in premature infants; Surfaxin LS, a Phase III trial product to improve ease of use for healthcare practitioners; and Aerosurf, an aerosolized KL4 surfactant that has completed first pilot Phase II clinical trial for the treatment of respiratory distress syndrome in premature infants.
The company has a license agreement with Philip Morris USA Inc. to use its capillary aerosolization technology for use with pulmonary surfactants for the respiratory diseases and conditions; and a strategic alliance agreement with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain.
Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
• | Surfaxin® (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants: The Company is conducting a comprehensive preclinical program to validate its optimized biological activity test (BAT), a key remaining issue that must be addressed to potentially gain U.S. Food and Drug Administration (FDA) marketing approval for Surfaxin in the United States. The Company has had several interactions with the FDA intended to ensure that the comprehensive preclinical program would ultimately satisfy the FDA. In January 2011, the Company announced that the FDA had provided guidance to increase the sample size of a specific data set by testing additional Surfaxin batches. To comply with the FDA's suggestion, the Company has successfully manufactured eight Surfaxin batches and presently plans to manufacture two additional Surfaxin batches for use in the comprehensive preclinical program. The Company presently plans to complete all related analytical testing and concordance studies, and be in a position to file a Surfaxin Complete Response in the third quarter of 2011. |
• | Surfaxin LSTM (lyophilized lucinactant) for neonatal RDS : The Company continues to advance this program. Its plans for 2011 include establishing a commercial-scale manufacturing capability at a cGMP-compliant contract manufacturer with expertise in lyophilized formulations and seeking regulatory guidance from the FDA and the European Medicines Agency (EMA) for the planned clinical development program. |
• | Aerosolization Technology : Recently, at the 2011 Pediatric Academic Societies Annual Meeting (PAS), new data was presented including: (i) a collaborative study indicating that aerosolized KL4 surfactant significantly improved lung function and survival when treating Acute Lung Injury in a well established preclinical model of this severe respiratory condition, (ii) a dose-ranging assessment of aerosolized KL4 surfactant in a widely recognized preclinical model of RDS, demonstrating significant improvement in lung function, lung structural integrity and pulmonary inflammatory mediator profile following treatment with aerosolized KL4 surfactant versus controls, and (iii) a study highlighting the Company's novel patient interface technology intended to increase the efficiency of pulmonary aerosol drug delivery to patients requiring positive pressure ventilatory support. |
| Regarding the Company's lead aerosolized KL4 surfactant program, Aerosurf® (aerosolized lucinactant for neonatal RDS), data from the preclinical dose ranging assessment study presented at PAS mentioned above suggests that, out of several doses tested, KL4 surfactant delivered via the Company's proprietary capillary aerosol generator during a 20 to 30 minute dosing interval results in the most favorable physiologic outcomes. This study provides guidance for future clinical dosing strategies for this program. The Company's plans for 2011 include finalizing the clinical and potential commercial design of the capillary aerosol generator, finalizing the clinical and potential commercial design for the novel patient interface, and seeking regulatory guidance in the U.S. and Europe for the planned development program. |
Investor Relations Contacts
2010-11 Press Releases
May 13, 2011 10-Q http://ih.advfn.com/p.php?pid=nmona&article=47677338
May 13, 2011 http://ih.advfn.com/p.php?pid=nmona&article=47666790 A Brighter Decade Ahead for Biotech - Equity Research on Discovery Laboratories and Mylan Inc
May 11, 2011 8k http://ih.advfn.com/p.php?pid=nmona&article=47626029
May 19, 2010
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval
May 14, 2010
Discovery Labs' Phase 2a Aerosurf® Study Published in Journal of Aerosol Medicine and Pulmonary Drug Delivery
April 27, 2010
Discovery Labs Provides Updates on Surfaxin®, Other Key Programs and First Quarter 2010 Financial Results
March 10, 2010
Discovery Labs Reports Fourth Quarter 2009 Financial Results and Provides Business Update
February 23, 2010
Discovery Labs Announces Completion of $16.5 Million Public Offering
February 18, 2010
Discovery Labs Prices $16.5 Million Public Offering of Common Stock and Warrants
February 17, 2010
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants
February 16, 2010
Discovery Labs Receives FDA Guidance Regarding Pathway to Potential SURFAXIN® Approval
January 19, 2010
POPG, a Key Component of Discovery Labs KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach
Management Team View Bio
W. Thomas Amick, Interim CEO
Russell Clayton, D.O.
Vice President, Academic and Medical Affairs, Acting Head, Regulatory Affairs and Preclinical Research
Kathryn Cole
Senior Vice President, Human Resources
John G. Cooper
Executive Vice President, Chief Financial Officer
David L. Lopez, C.P.A., Esq.
Executive Vice President, General Counsel
Charles F. Katzer
Senior Vice President, Manufacturing Operations
Thomas F. Miller, Ph.D., MBA
Senior Vice President, Commercialization & Corporate Development
Gerald J. Orehostky
Senior Vice President, Quality Operations
Robert Segal, M.D., F.A.C.P.
Senior Vice President, Medical & Scientific Affairs, Chief Medical Officer
Mary B. Templeton, Esq.
Senior Vice President, Deputy General Counsel
Do your own DD & trade smart
(DSCO) Pre-Market Trading (DSCO) After Hours Trading
(DSCO) Short
Technical Indicators (Barchart)
Yahoo! Finance (i.e Real-Time)
Last update: June 03,2010
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |